Denali Therapeutics (DNLI) - Stock Price & Dividends

Denali Therapeutics Inc. is a biopharmaceutical company that develops innovative treatments for neurodegenerative diseases and lysosomal storage diseases. Their mission is to create life-changing medicines that can effectively cross the blood-brain barrier, a significant challenge in treating brain-related disorders.

The company's pipeline includes several promising programs, such as DNL310 ETV, an enzyme replacement therapy for Mucopolysaccharidosis II (MPS II), a rare genetic disorder. They are also working on TAK-594/DNL593, a potential treatment for frontotemporal dementia-granulin, a devastating brain disorder that affects behavior, language, and movement.

In addition, Denali Therapeutics is developing DNL126 for Mucopolysaccharidosis IIIA (MPS IIIA), a severe genetic disorder that affects children, and DNL622 for Mucopolysaccharidosis I (MPS I), also known as Hurler syndrome. These programs utilize the company's proprietary Transport Vehicle (TV) technology, which enables the delivery of large molecules across the blood-brain barrier.

Denali Therapeutics also has a range of small molecule programs, including BIIB122/DNL151, a LRRK2 inhibitor for Parkinson's disease, and SAR443820/DNL788, a RIPK1 inhibitor for central nervous system (CNS) diseases. They are also working on DNL343, an eIF2B activator for amyotrophic lateral sclerosis (ALS), and SAR443122/DNL758, a RIPK1 inhibitor for peripheral inflammatory diseases.

The company has established collaborations with leading biotech and pharmaceutical companies, including Biogen, Genzyme, Takeda, F-star, and Genentech. These partnerships enable Denali Therapeutics to accelerate the development of their innovative treatments and bring them to patients faster.

Founded in 2013, Denali Therapeutics is headquartered in South San Francisco, California, and has undergone significant growth and transformation, including a name change from SPR Pharma Inc. in 2015. Today, the company is a leader in the development of novel therapies for brain-related disorders, with a strong focus on innovation, collaboration, and patient-centricity.